Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 14/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 1.00 |
| ▸ | HPGD | P15428 | 8/20 | 1.00 |
| ▸ | GAA | P10253 | 7/20 | 1.00 |
| ▸ | MAPT | P10636 | 10/20 | 0.80 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.80 |
| ▸ | GLA | P06280 | 3/20 | 0.80 |
| ▸ | HTT | P42858 | 3/20 | 0.80 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.80 |
| ▸ | USP2 | O75604 | 1/20 | 0.80 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.80 |
| ▸ | RXFP1 | Q9HBX9 | 7/20 | 0.80 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.78 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.72 |
| ▸ | TSHR | P16473 | 1/20 | 0.69 |
| ▸ | ATM | Q13315 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12562437 | 0.90 | KDM4E (0.81) | KDM4EALDH1A1HPGDGAAMAPT | |
| SCHEMBL5013124 | 0.84 | KDM4E (0.73) | KDM4EALDH1A1HPGDGAAMAPT | |
| SCHEMBL4053028 | 0.84 | KDM4E (0.72) | KDM4EALDH1A1HPGDGAAMAPT | |
| SCHEMBL4051863 | 0.81 | KDM4E (0.67) | KDM4EALDH1A1HPGDGAAMAPT | |
| SCHEMBL20467123 | 0.81 | KDM4E (0.67) | KDM4EALDH1A1HPGDGAAMAPT | |
| SCHEMBL426279 | 0.80 | KDM4E (1.00) | KDM4EALDH1A1HPGDGAAMAPT | |
| SCHEMBL19805083 | 0.78 | KDM4E (0.80) | KDM4EALDH1A1HPGDGAAMAPT | |
| SCHEMBL13186375 | 0.77 | KDM4E (0.62) | KDM4EALDH1A1HPGDGAAMAPT | |
| SCHEMBL23657476 | 0.77 | MEN1 (0.82) | KDM4EALDH1A1HPGDGAAMAPT | |
| SCHEMBL4051300 | 0.76 | KDM4E (0.71) | KDM4EALDH1A1HPGDGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11339178-B2 | Inhibitors of microbial beta-glucuronidase enzymes and uses thereof | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2022-05-24 | — | — | US | disclosed |
| US-20190330237-A1 | INHIBITORS OF MICROBIAL BETA-GLUCURONIDASE ENZYMES AND USES THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2019-10-31 | — | — | US | disclosed |
| WO-2018142365-A1 | INHIBITORS OF MICROBIAL BETA-GLUCURONIDASE ENZYMES AND USES THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2018-08-09 | — | — | WO | disclosed |
| WO-2018017874-A1 | INHIBITORS OF MICROBIAL BETA-GLUCURONIDASE ENZYMES AND USES THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2018-01-25 | — | — | WO | disclosed |
| EP-3181568-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | Siga Technologies, Inc. (US) | 2017-06-21 | — | — | EP | disclosed |
| EP-3181568-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | Siga Technologies, Inc. (US) | 2017-06-21 | — | — | EP | disclosed |
| US-20170121344-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | SIGA TECHNOLOGIES, INC. (US) | 2017-05-04 | — | — | US | disclosed |
| US-20170121344-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | SIGA TECHNOLOGIES, INC. (US) | 2017-05-04 | — | — | US | disclosed |
| US-20170121344-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | SIGA TECHNOLOGIES, INC. (US) | 2017-05-04 | — | — | US | disclosed |
| EP-2400845-B1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | SIGA TECH INC (US) | 2017-02-22 | — | — | EP | disclosed |
| US-20120022046-A1 | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections | SIGA TECHNOLOGIES, INC. | 2012-01-26 | — | — | US | disclosed |
| US-20120022046-A1 | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections | SIGA TECHNOLOGIES, INC. | 2012-01-26 | — | — | US | disclosed |
| US-20120022046-A1 | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections | SIGA TECHNOLOGIES, INC. | 2012-01-26 | — | — | US | disclosed |
| US-8058285-B2 | Phosphodiesterase-4 (PDE-4) inhibitors; for treating bronchial asthma, COPD, rheumatoid arthritis (RA), osteoarthritis, cystic fibrosis, Guillain-Barresyndrome, Crohn's disease, ulcerative colitis, psoriasis, atopic dermatitis, allergic eczemas | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2011-11-15 | — | — | US | disclosed |
| US-8058285-B2 | Phosphodiesterase-4 (PDE-4) inhibitors; for treating bronchial asthma, COPD, rheumatoid arthritis (RA), osteoarthritis, cystic fibrosis, Guillain-Barresyndrome, Crohn's disease, ulcerative colitis, psoriasis, atopic dermatitis, allergic eczemas | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2011-11-15 | — | — | US | disclosed |
| WO-2010099166-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | SIGA TECHNOLOGIES, INC. (US) | 2010-09-02 | — | — | WO | disclosed |
| EP-1773840-B1 | SUBSTITUTED PYRIDO[3',2':4,5]THIENO[3,2-D]PYRIMIDINES AND PYRIDO[3',2':4,5]FURO[3,2-D]-PYRIMIDINES FOR USE AS INHIBITORS OF PDA-4 AND/OR TNF-ALPHA RELEASE | MEDICINES CO LEIPZIG GMBH (DE) | 2010-01-20 | — | — | EP | disclosed |
| US-20080160028-A1 | SUBSTITUTED PYRIDO [3', 2': 4, 5] THIENO [3, 2-D] PYRIMIDINES AND PYRIDO [3', 2': 4, 5] FURO [3, 2-D] PYRIMIDINES USED AS INHIBITORS OF THE PDE-4 AND/OR THE RELEASE OF TNF-ALPHA | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2008-07-03 | — | — | US | disclosed |
| US-20080160028-A1 | SUBSTITUTED PYRIDO [3', 2': 4, 5] THIENO [3, 2-D] PYRIMIDINES AND PYRIDO [3', 2': 4, 5] FURO [3, 2-D] PYRIMIDINES USED AS INHIBITORS OF THE PDE-4 AND/OR THE RELEASE OF TNF-ALPHA | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2008-07-03 | — | — | US | disclosed |
| WO-2006010567-A1 | SUBSTITUTED PYRIDO[3', 2': 4, 5]THIENO[3,2-D]PYRIMIDINES AND PYRIDO[3', 2': 4, 5]FURO[3, 2, D]PYRIMIDINES USED AS INHIBITORS OF THE PDE-4 AND/OR THE RELEASE OF TNF$G(A) | CURACYTE DISCOVERY GMBH (DE) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022046-A1 | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections | TTPA, TPMT, SLC19A2 | KDM4E 1399/4885ALDH1A1 1271/4885HPGD 188/4885 |
| US-20080160028-A1 | SUBSTITUTED PYRIDO [3', 2': 4, 5] THIENO [3, 2-D] PYRIMIDINES AND PYRIDO [3', 2': 4, 5] FURO [3, 2-D] PYRIMIDINES USED AS INHIBITORS OF THE PDE-4 AND/OR THE RELEASE OF TNF-ALPHA | PDE4A, PDE3B, PDE4B | KDM4E 1558/4885ALDH1A1 367/4885HPGD 149/4885 |
| US-11339178-B2 | Inhibitors of microbial beta-glucuronidase enzymes and uses thereof | GUSB, ENGASE, MGAM | KDM4E 4075/4885ALDH1A1 511/4885HPGD 548/4885 |
| US-20190330237-A1 | INHIBITORS OF MICROBIAL BETA-GLUCURONIDASE ENZYMES AND USES THEREOF | GUSB, ENGASE, MGAM | KDM4E 4075/4885ALDH1A1 511/4885HPGD 548/4885 |
| US-20170121344-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | TTPA, TPMT, SLC19A2 | KDM4E 1403/4885ALDH1A1 1400/4885HPGD 205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.